Jan van Es

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry

Giuseppe Boriani, Marco Proietti, Cécile Laroche et al. · EP Europace · 2017 · 166 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry

Giuseppe Boriani, Marco Proietti, Cécile Laroche et al. · EP Europace · 2019 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy

M. A. G. M. Olimulder, Jan van Es, Michel A. Galjee · Netherlands Heart Journal · 2009 · 71 citations · Full text

Medicine, Cardiology, Infectious Diseases +16

Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

Giulio Francesco Romiti, Marco Proietti, Marco Vitolo et al. · BMC Medicine · 2022 · 70 citations · Full text

Medicine, Cardiology, Internal Medicine +16